Introduction: Moving beyond end-product testing
What is process analytical technology?
How PAT supports faster pharmaceutical development
From pilot scale to commercial manufacturing
PAT in powder processing and tablet production
Why PAT matters for medicine quality and patient outcomes
Process Analytical Technology (PAT) enables pharmaceutical manufacturers to monitor and control critical process variables in real time, shifting quality assurance from end-product testing to proactive process understanding. Combined with Quality by Design principles, PAT supports robust scale-up, consistent medicine quality, and more efficient, science-based pharmaceutical manufacturing.
Image credit: Gorodenkoff/Shutterstock.com
Pharmaceutical manufacturing once relied heavily on testing finished batches and hoping for consistency. Process Analytical Technology (PAT) supplements traditional testing with timely, often real-time insights into critical stages of drug production.1
Introduction: Moving beyond end-product testing
Until the late 1990s, quality assurance in the pharmaceutical industry largely depended on the traditional strategy of manufacturing the product, then testing a sample of the finished batch against a specification. A passing batch was shipped, and a failing batch was reprocessed or discarded, often without a clear understanding of what had gone wrong. This reliance on end-product testing meant that quality was something to be confirmed at the end stage rather than engineered, resulting in losses in time and resources.1
The United States (U.S.) Food and Drug Administration (FDA)'s PAT initiative, formalized in 2004, addressed this problem by defining PAT as a system for designing, analyzing, and controlling manufacturing through timely measurements of critical quality and performance attributes of raw and in-process materials and processes, with the broader aim of ensuring that the finished product consistently meets its intended specifications.1–3
PAT emerged as part of the broader transition toward Quality by Design (QbD) and risk-based pharmaceutical development. QbD asks manufacturers to define quality objectives upfront and build processes capable of meeting them, rather than discovering gaps afterward. Together, these frameworks have brought about a shift in pharmaceutical manufacturing, where quality must be understood and controlled as the process unfolds, and not tested for after the fact.4,5
What is process analytical technology?
PAT refers to the combination of analytical instruments, data systems, and monitoring strategies used to design, analyze, and control pharmaceutical materials and processes through timely measurements, so that manufacturers can intervene before a deviation becomes a defect, rather than waiting for laboratory results on a finished batch and discovering the errors after the fact. PAT systems commonly combine in-line, on-line, or at-line measurements with chemometric or multivariate models and may support feed-forward or feedback process control.1,3,8
Two major concepts form the foundation of this approach. Critical Quality Attributes (CQAs) are physical, chemical, biological, or microbiological properties that must remain within appropriate limits to ensure product quality, such as content uniformity, dissolution behavior, or moisture level. Critical Process Parameters (CPPs) are process parameters whose variability can affect a CQA and therefore require monitoring or control, such as temperature, mixing speed, or spray rate. The central task of PAT tools is to measure relevant attributes and help characterize and control the relationship between CPPs and CQAs.1,6
A range of analytical tools is employed for the process, each suited to particular materials and process stages. Near-infrared spectroscopy is among the most widely adopted due to its ability to probe molecular vibrations without destroying the sample. It is well-suited to monitoring blending, granulation, drying, and coating operations in solid oral dosage manufacturing. Raman spectroscopy is widely used to characterize the composition of chemicals in liquid, solid, and powder forms, making it valuable for tracking polymorphic form, blend uniformity, and coating thickness.2–4
Fourier-transform infrared spectroscopy provides molecularly specific information from fundamental vibrational bands and can be applied to material identification, composition, and moisture-related measurements.2,3
Additionally, particle size analysis, performed through tools such as focused beam reflectance measurement or laser diffraction, tracks how granules and crystals grow or break apart during processing, and has direct consequences for flowability and dissolution, with applications extending to crystallization and selected vaccine or adjuvant-manufacturing processes. Moisture measurement systems, whether based on near-infrared absorbance or microwave resonance, also help avert the instability and degradation that excess water content can introduce into a formulation.2,3
Download the free PDF to explore Process Analytical Technology in pharmaceutical manufacturing.
How PAT supports faster pharmaceutical development
Knowledge of how a formulation responds to mixing time, drying temperature, or compaction force becomes the foundation for a smoother scale-up rather than fresh trial and error at each site. This grounding knowledge can shorten development timelines. A process characterized through PAT and Quality by Design may reach commercial scale with a justified design space and control strategy, reducing the risk and disruption of scale-up failures.6
The same knowledge also strengthens regulatory submissions. Quality by Design can support more informative submissions and potentially streamline regulatory review because detailed product and process understanding gives reviewers a clearer basis for assessing how quality will be maintained across the product's life cycle. In essence, PAT converts pharmaceutical development from a trial-and-error refinement process into a structured, data-driven framework.4,5
From pilot scale to commercial manufacturing
Moving a process from bench to production line also introduces challenges that are often not obvious at smaller scales. Mixing efficiency is a major challenge, where a blend that is uniform in a small vessel may behave differently in a larger blender, where flow patterns and residence times change substantially. Heat and mass transfer present similar difficulties, especially during lyophilization or freeze-drying steps, since equipment-dependent heat-transfer coefficients, pressure-control capabilities, sublimation capacity, and freezing behavior may differ between laboratory and commercial dryers.5,7
Continuous monitoring through PAT offers a solution to many of these challenges. In-line tools such as near-infrared or Raman analyzers give manufacturers visibility into the same critical quality attributes throughout scale-up, rather than inferring commercial performance from pilot data alone. This allows the production conditions and results to be verified and refined as conditions change.3
Early detection of process drift is perhaps the most consequential advantage. Parametric release programs for sterile products rely on this principle by controlling sterilization parameters so tightly that the process itself assures sterility, allowing release decisions in defined applications to be based on documented process control rather than sterility testing alone.8
PAT in powder processing and tablet production
Image credit: Mai.Chayakorn/Shutterstock.com
Solid oral dosage forms, the most common way medicines reach patients, depend on a sequence of powder-handling steps where PAT has found some of its most critical applications.
Blend uniformity is the foundational process for tablet production, since an unevenly mixed powder bed influences the uniformity of drug content among individual tablets. Near-infrared probes within blenders track homogeneity as mixing proceeds, letting operators identify an acceptable endpoint rather than relying on a fixed time that may under- or overmix a batch.5
Moreover, granulation also depends on identifying the correct endpoint, since too little binder will result in weak granules and too much will create an overwetted mass. Tools such as near-infrared spectroscopy, focused beam reflectance measurement, and acoustic emission sensors determine endpoints from the granules' actual state rather than a predetermined time.2
Moisture control is an equally important part of granulation, and in PAT protocols, in-line near-infrared and microwave sensors give continuous visibility into drying, guarding against both excess moisture and unnecessary over-drying.2
Additionally, near-infrared or Raman probes can monitor drug-content-related attributes during tableting, while near-infrared and terahertz imaging can assess coating thickness against dissolution targets. Across each step, real-time measurement confirms progress toward the quality target, rather than discovering the outcome only at the end.2
Why PAT matters for medicine quality and patient outcomes
The case for PAT extends well beyond manufacturing efficiency, since it exists to protect the patients who eventually take the medicine. Consistent drug performance is the most direct benefit. A tablet's dissolution behavior, release rate, and bioavailability depend on attributes established during manufacturing. Monitoring relevant material attributes and process conditions in real time supports more predictable performance from one dose to the next, which is especially important for medicines with a narrow therapeutic window.6
Reduced batch-to-batch variability also helps ensure that factors such as release rate and bioavailability are not altered across batches during large-scale production. Continuous PAT monitoring catches and corrects variation as it emerges rather than after a batch is complete, also reducing loss of resources.7
The manufacturing reliability built through PAT monitoring benefits the whole supply chain. Studies note that PAT goals in biopharmaceutical manufacturing include shorter cycle times, less waste, and real-time product release, which can improve throughput and reduce avoidable production delays. Additionally, Quality by Design provides regulators with a stronger basis for oversight than finished-product specifications alone, thereby providing greater regulatory confidence and supporting lifecycle management and continual improvement. Moreover, PAT-enabled monitoring supports more efficient production of vaccines, biologics, and complex and critical therapeutics where reliable manufacturing is paramount.3,8
References
- Zhang, L., & Mao, S. (2017). Application of quality by design in the current drug development. Asian journal of pharmaceutical sciences, 12(1), 1–8. DOI:10.1016/j.ajps.2016.07.006, https://www.sciencedirect.com/science/article/pii/S1818087616301056
- Kim, E. J., Kim, J. H., Kim, M.-S., Jeong, S. H., & Choi, D. H. (2021). Process Analytical Technology Tools for Monitoring Pharmaceutical Unit Operations: A Control Strategy for Continuous Process Verification. Pharmaceutics, 13(6), 919. DOI:10.3390/pharmaceutics13060919, https://www.mdpi.com/1999-4923/13/6/919
- Gerzon, G., Sheng, Y., & Kirkitadze, M. (2022). Process Analytical Technologies – Advances in bioprocess integration and future perspectives. Journal of Pharmaceutical and Biomedical Analysis, 207, 114379. DOI:10.1016/j.jpba.2021.114379, https://www.sciencedirect.com/science/article/pii/S0731708521008209
- Calhan, S. D., Eker, E. D., & Sahin, N. O. (2017). Quality by design (QbD) and process analytical technology (PAT) applications in pharmaceutical industry. European Journal of Chemistry, 8(4), 430–433. DOI:10.5155/eurjchem.8.4.430-433.1667, https://www.eurjchem.com/index.php/eurjchem/article/view/1667
- Pramod, K., Tahir, M. A., Charoo, N. A., Ansari, S. H., & Ali, J. (2016). Pharmaceutical product development: A quality by design approach. International journal of pharmaceutical investigation, 6(3), 129–138. DOI:10.4103/2230-973X.187350, https://journals.lww.com/iphr/fulltext/2016/06030/pharmaceutical_product_development__a_quality_by.2.aspx
- Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. The AAPS journal, 16(4), 771–783. DOI:10.1208/s12248-014-9598-3, https://link.springer.com/article/10.1208/s12248-014-9598-3
- Tchessalov, S., Shalaev, E., Bhatnagar, B., Nail, S., Alexeenko, A., Jameel, F., Srinivasan, J., Dekner, M., Sahni, E., Schneid, S., Kazarin, P., McGarvey, O., Van Meervenne, B., Kshirsagar, V., Pande, P., Philipp, J., Sacha, G., Wu, K., Azzarella, J., Shivkumar, G., … Bhatt, S. (2022). Best Practices and Guidelines (2022) for Scale-Up and Tech Transfer in Freeze-Drying Based on Case Studies. Part 1: Challenges during Scale Up and Transfer. AAPS PharmSciTech, 24(1), 11. DOI:10.1208/s12249-022-02463-x, https://link.springer.com/article/10.1208/s12249-022-02463-x
- Riley, B. S., & Li, X. (2011). Quality by design and process analytical technology for sterile products - where are we now?. AAPS PharmSciTech, 12(1), 114–118. DOI:10.1208/s12249-010-9566-x, https://link.springer.com/article/10.1208/s12249-010-9566-x
Further Reading
Last Updated: Jul 13, 2026